Genoway Asset Resilience Ratio
Genoway asset resilience ratio. Genoway (ALGEN) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALGEN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genoway (2006–2024)
Asset resilience ratio of Genoway from 2006 to 2024. This chart shows how Genoway's Asset Resilience Ratio has changed over time. Read total liabilities of Genoway for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genoway's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALGEN asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Genoway maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Genoway Industry Peers by Asset Resilience Ratio
Compare Genoway's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Genoway Asset Resilience Ratio by Year (2006–2024)
Genoway asset resilience ratio by year from 2006 to 2024. The table below shows the annual Asset Resilience Ratio data for Genoway.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€31.80 Million ≈ $37.18 Million |
-- |
| 2023-12-31 | 1.64% | €523.40K ≈ $611.91K |
€31.84 Million ≈ $37.23 Million |
+1.75pp |
| 2022-12-31 | -0.11% | €-36.30K ≈ $-42.44K |
€32.92 Million ≈ $38.49 Million |
+0.00pp |
| 2021-12-31 | -0.11% | €-36.30K ≈ $-42.44K |
€32.50 Million ≈ $37.99 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€27.57 Million ≈ $32.23 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.15 Million ≈ $22.39 Million |
-- |
| 2018-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.69 Million ≈ $23.02 Million |
-- |
| 2017-12-31 | 0.01% | €1.48K ≈ $1.73K |
€17.17 Million ≈ $20.07 Million |
0.00pp |
| 2016-12-31 | 0.01% | €1.48K ≈ $1.73K |
€11.70 Million ≈ $13.68 Million |
+0.01pp |
| 2015-12-31 | 0.01% | €739.00 ≈ $863.97 |
€10.78 Million ≈ $12.60 Million |
0.00pp |
| 2014-12-31 | 0.01% | €739.00 ≈ $863.97 |
€10.38 Million ≈ $12.13 Million |
0.00pp |
| 2013-12-31 | 0.01% | €730.00 ≈ $853.45 |
€9.75 Million ≈ $11.40 Million |
-1.79pp |
| 2009-12-31 | 1.79% | €200.42K ≈ $234.31K |
€11.17 Million ≈ $13.06 Million |
-3.11pp |
| 2008-12-31 | 4.91% | €502.00K ≈ $586.89K |
€10.23 Million ≈ $11.96 Million |
-16.86pp |
| 2006-12-31 | 21.77% | €1.54 Million ≈ $1.80 Million |
€7.08 Million ≈ $8.27 Million |
-- |
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more